How COVID Quarantine May Have Fueled Infantile AD➜ DOI: 10.1111/all.16561Environmental exposures in early life are increasingly linked to the development of AD. China’s COVID-19 lockdown drastically altered infant environmental contact. This Shanghai birth cohort study examined 2204 mother–child pairs, comparing pre- and post-quarantine births. Infants exposed to early-life quarantine had significantly higher rates of AD by [...] Read More
Crusted Scabies and Dupilumab: A Case from Brazil➜ DOI: 10.25259/IJDVL_753_2024Crusted scabies is typically seen only in immunocompromised patients. This case from Brazil underscores the need for heightened vigilance in atopic dermatitis (AD) patients undergoing dupilumab treatment, particularly if they experience a sudden worsening of pruritus or lesions. More broadly, it highlights the risk of parasitic infections [...] Read More
Defining a good indication of nemoluzimab based on clinical criteria➜ DOI: 10.1111/1346-8138.17626Nemolizumab is an effective treatment for pruritus in atopic dermatitis, but it has a relatively high incidence of cutaneous adverse events (cAEs). To optimize the use of nemolizumab, Japanese researchers investigated the relationship between baseline severity in specific body areas and the frequency of cAEs. [...] Read More
Season of birth shapes human milk microbiome➜ DOI: 10.1111/all.16469In this Australian study, the season of infant birth emerged as the strongest determinant of the microbiome community structure with impacts on five of the most abundant taxa. This seasonal effect is not correlated with a bad taxon more prevalent in winter where AD is more common. The [...] Read More
Better spatial tissue imaging techniques to differentiate CTCL and AD➜ DOI: 10.1038/s41540-024-00474-xCutaneous T-cell lymphomas (CTCLs) can be difficult to distinguish from inflammatory skin conditions like atopic dermatitis (AD). Multi-antigen imaging protein abundance maps were analyzed with spatial graphs inferred from the cells' positions in the tissue samples. Characteristic patterns of skin tissue organization allowed a high-precision [...] Read More
Fecal microbiota transplantation (FMT): first RCT.➜ DOI: 10.1111/all.16372This Chinese randomized, double-blind, placebo-controlled clinical trial, studied the efficacy and safety assessment of FMT for moderate-to-severe adult patients with AD. All patients received FMT or placebo as capsules sourced for FMT verum from 2 strictly screened healthy donors once a week for 3 weeks, in addition to their [...] Read More
Conjunctival transcriptomic profile predicts dupilumab ocular adverse events➜ DOI: 10.1016/j.jid.2024.08.024DNA microarray analysis was used to compare the transcriptome of AD patients’ conjunctival cells collected before and 4 months after initiating dupilumab treatment. Interestingly, patients developing ocular adverse effects had both before and after treatment a similar transcriptome signature, characterized by the over-expression of several genes involved [...] Read More
Vernal keratoconjunctivitis (VKC) and AD➜ DOI: 10.2147/OPTH.S472826The importance of ophthalmological co-morbidities of AD was recently highlighted because of the large literature on dupilumab and ocular surface disorders, but several other aspects are currently neglected. VKC is a refractory ocular allergic disorder that mainly affects boys, and long-term follow-up has been rarely reported. The Department of Ophthalmology [...] Read More
Release of the 4th Davos declaration on AD and Allergy➜ DOI: 10.1111/all.16247The 2022 Forum is now published with its usual “Declaration” signed by all participants. Besides the mounting burden of AD, attributed to significant environmental and lifestyle changes, the Forum acknowledged the progress in understanding AD and in developing targeted therapies but recognized a gap in [...] Read More
Cell therapy for atopic dermatitis➜ DOI: 10.1016/j.jaci.2024.06.021Mesenchymal stem cells (MSCs) have been found to play a role in regulating immune responses. Allogenic human bone marrow-derived clonal MSCs (hcMSCs) were administered intravenously weekly for 3 weeks in volunteers with moderate to severe atopic dermatitis (AD) by Korean investigators, with improvement of objective scores at 12 weeks, with [...] Read More